financetom
Business
financetom
/
Business
/
SaaS company Extreme Networks' Q4 revenue growth beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SaaS company Extreme Networks' Q4 revenue growth beats estimates
Aug 6, 2025 4:56 AM

Overview

* Extreme Networks ( EXTR ) Q4 revenue up 20% yr/yr, beating analyst expectations

* Non-GAAP EPS for Q4 at $0.25, surpassing analyst estimates

* SaaS ARR increased 24% yr/yr, indicating strong subscription model growth

Outlook

* Extreme targets Q1 FY26 revenue between $292 mln and $300 mln

* Company expects Q1 FY26 non-GAAP EPS of $0.20 to $0.23

* Extreme sees FY26 revenue between $1,228 mln and $1,238 mln

* Company anticipates re-acceleration of revenue growth in FY26

Result Drivers

* GLOBAL DEMAND - Increased customer engagement in EMEA and APAC regions contributed to revenue growth, per CEO Ed Meyercord

* AI PLATFORM - Launch of Extreme Platform ONE, an AI-driven networking platform, is driving customer interest and market momentum

* EXPENSE MANAGEMENT - Prudent expense management led to strong cash flow, according to CFO Kevin Rhodes

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Beat $307 mln $299.90

Revenue mln (7

Analysts

)

Q4 Beat $0.25 $0.23 (7

Adjusted Analysts

EPS )

Q4 EPS -$0.06

Q4 62.3%

Adjusted

Gross

Margin

Q4 15.2%

Adjusted

Operatin

g Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the communications & networking peer group is "buy"

* Wall Street's median 12-month price target for Extreme Networks Inc ( EXTR ) is $20.00, about 11.6% above its August 5 closing price of $17.67

* The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
American Water Works Says Pennsylvania Court Dismisses Challenge to  Wastewater Asset Acquisition
American Water Works Says Pennsylvania Court Dismisses Challenge to Wastewater Asset Acquisition
Oct 2, 2024
09:02 AM EDT, 09/30/2024 (MT Newswires) -- American Water Works ( AWK ) said Friday the Pennsylvania Commonwealth Court has dismissed appeals challenging the Pennsylvania Public Utility Commission's approval of its $230 million acquisition of Butler Area Sewer Authority's wastewater assets. Following the court decision, American Water Works ( AWK ) said its subsidiary Pennsylvania-American Water will move forward to...
Astria Therapeutics' Potential Hereditary Angioedema Treatment Gets FDA Orphan Drug Designation
Astria Therapeutics' Potential Hereditary Angioedema Treatment Gets FDA Orphan Drug Designation
Oct 2, 2024
09:01 AM EDT, 09/30/2024 (MT Newswires) -- Astria Therapeutics ( ATXS ) said Monday that the US Food and Drug Administration has granted Orphan Drug Designation to navenibart for the treatment of hereditary angioedema. Orphan status is given medicines intended to prevent, diagnose and treat rare diseases or disorders that affect less than 200,000 people in the US, Astria said....
TotalEnergies to sign $10 bln deal on Suriname's first offshore project, sources say
TotalEnergies to sign $10 bln deal on Suriname's first offshore project, sources say
Oct 2, 2024
PARIS/PARAMARIBO, Sept 30 - French oil major TotalEnergies will sign a final investment decision (FID) on Tuesday for a more than $10 billion offshore oil and gas development in Suriname, the country's first, said four sources with knowledge of the project. Located in Block 58 about 140 km off the coast of the South American country, the Gran Morgu field...
Calidi Biotherapeutics Says FDA Clears Phase 1b/2 Trial of CLD-101 in High-Grade Glioma
Calidi Biotherapeutics Says FDA Clears Phase 1b/2 Trial of CLD-101 in High-Grade Glioma
Oct 2, 2024
09:02 AM EDT, 09/30/2024 (MT Newswires) -- Calidi Biotherapeutics ( CLDI/WS ) said Monday that the US Food and Drug Administration has cleared Northwestern University's investigational new drug application for the company's CLD-101 therapy, which uses stem cells to deliver engineered oncolytic adenoviruses. A phase 1b/2 trial of the investigational treatment is expected to begin late this year at the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved